The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Co. Advancing Drug Class With Broad Potential

Research Report

Dr. Thomas Shrader (09/13/2022)

This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion

Clive Maund (09/13/2022)

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

Streetwise Reports (09/12/2022)

One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report

Dr. Jonathan Aschoff (09/12/2022)

Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials

Streetwise Reports (09/08/2022)

Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients.

Tags: Medical DevicesBiotechnology / Pharmaceuticals

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report

Dr. Ram Selvaraju (09/08/2022)

This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Biopharma Co. Receives Approval From FDA Panel for ALS Drug

Streetwise Reports (09/08/2022)

Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Transforming Injected Drugs Into Pills

Research Report

Dr. Ram Selvaraju (09/07/2022)

This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.

Tags: Biotechnology / Pharmaceuticals

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion

Clive Maund (09/07/2022)

Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report

Dr. Tony Butler (09/06/2022)

The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Newsletter Update

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

Streetwise Reports (09/04/2022)

One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.

Tags: Biotechnology / Pharmaceuticals

Denmark Co. To Buy US Biopharma Co. for $1.1 Billion

Streetwise Reports (09/02/2022)

Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease.

Tags: Biotechnology / Pharmaceuticals

Newsletter Update

Expert Rates Pharma Co. An Immediate Buy

Contributed Opinion

Chris Temple (09/01/2022)

Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.

Tags: Biotechnology / Pharmaceuticals

FDA OKs Biopharma to Trial New Cell Therapy

Research Report

Mitchell Kapoor (08/30/2022)

Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Plans IND Filing for Dry Eye Disease Drug in Q4/22

(08/30/2022)

Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23.

Tags: Biotechnology / Pharmaceuticals

Delay in New Drug Filing Now Could Yield Benefits Later

Research Report

Hartaj Singh (08/29/2022)

The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

ACC Recommends Approved Drug for Lowering LDL

Research Report

Joseph Pantginis (08/29/2022)

This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. To Provide HHS With Smallpox Drug

Streetwise Reports (08/29/2022)

Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula

Streetwise Reports (08/26/2022)

A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.

Tags: Biotechnology / Pharmaceuticals

First Data Due by Year End 2022 From Study of New HAE Drug

Research Report

Hartaj Singh (08/24/2022)

Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

New Schizophrenia Drug Has Chance of Getting FDA Approved

Research Report

Dr. Thomas Shrader (08/24/2022)

The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Newsletter Update

Hedge Fund Doubles Position in Biotech Co.

Streetwise Reports (08/23/2022)

A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.

Tags: Biotechnology / Pharmaceuticals

Expert Sees Even More 'Good News' From Pharma Co.

Contributed Opinion

Clive Maund (08/23/2022)

Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Multiple Shots on Goal

Research Report

Justin Kim (08/22/2022)

This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

Price Target on Cancer Drug Co. Boosted

Research Report

Joseph Pantginis (08/22/2022)

The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 51 to 75 of 147 Prev Next